Table 2.
Classification performance of SLMS and other traditional gastrointestinal tumor-related biomarkers in EGC patients of different cohorts.
| cohort (EGC vs HD) | panel | Accuracy (95%CI) | Sensitivity (95%CI) | Specificity (95%CI) |
|---|---|---|---|---|
| Training cohort (109 vs 227) | SLMS | 0.964 (0.938~0.981) | 0.945 (0.884~0.980) | 0.974 (0.943~0.990) |
| CEA | 0.673 (0.620~0.723) | 0.064 (0.026~0.128 | 0.965 (0.932~0.985 | |
| CA19-9 | 0.676 (0.623~0.725) | 0.028 (0.006~0.008) | 0.987 (0.962~0.997) | |
| CA72-4 | 0.619 (0.565~0.671) | 0.077 (0.003~0.140) | 0.881 (0.832~0.920) | |
| Testing cohort (24 vs 39) | SLMS | 0.984 (0.915~1.000) | 0.958 (0.789~0.999) | 1.000 (0.910~1.000) |
| CEA | 0.651 (0.520~0.767) | 0.125 (0.027~0.324) | 0.974 (0.865~0.999) | |
| CA19-9 | 0.619 (0.488~0.739) | 0.042 (0.001~0.211) | 0.974 (0.865~0.999) | |
| CA72-4 | 0.603 (0.472~0.724) | 0.201 (0.071~0.422) | 0.846 (0.695~0.941) | |
| External validation cohort (43 vs 98) | SLMS | 0.922 (0.865~0.960) | 0.977 (0.877~0.994) | 0.898 (0.820~0.50) |
| CEA | 0.702 (0.619~0.776) | 0.070 (0.001~0.190) | 0.980 (0.928~0.998) | |
| CA19-9 | 0.716 (0.634~0.789) | 0.093 (0.026~0.221) | 0.990 (0.945~1.000) | |
| CA72-4 | 0.660 (0.575~0.737) | 0.163 (0.068~0.307) | 0.878 (0.796~0.935) | |
| Predictive cohort (35 vs 69) | SLMS | 0.923 (0.854~0.966) | 0.886 (0.732~0.968) | 0.942 (0.858~0.984) |
| CEA | 0.702 (0.604~0.788) | 0.143 (0.005~0.303) | 0.986 (0.922~1.000) | |
| CA19-9 | 0.692 (0.594~0.779) | 0.086 (0.018~0.231) | 1.000 (0.948~1.000) | |
| CA72-4 | 0.654 (0.554~0.745) | 0.171 (0.066~0.337) | 0.899 (0.802~0.958) |
CA19-9 carbohydrate antigen 199, CA72-4 carbohydrate antigen 724, CEA carcinoembryonic antigen, CI confidence interval, EGC early-stage gastric cancer, HD healthy donor, SLMS serum lipid metabolic signature.